Medovex Corp. (NASDAQ:MDVX), (“Medovex” or the “Company”), a developer of medical technology products, today announced it has received CE Mark approval for the DenerveX™ System allowing the Company to market the DenerveX System in Europe.
Patrick Kullmann, Medovex President and COO, stated, “We are clearly pleased to have accomplished this important milestone not just for our shareholders, but for all of those suffering from often debilitating lower back pain associated with Facet Joint Syndrome. The CE Mark indicates a product’s compliance with applicable EU regulations and enables the commercialization of the DenerveX System in European Countries.”
Medovex Corp. (NASDAQ: MDVX) has reported EPS of $(0.14) for its last quarter.
To generate the revenue, Medovex Corp. recorded direct expenses amounting to $6,221, being the cost of sales. After subtracting the same, the firm closed with gross profit of $(6,221).
Let?s look into the technical of the stock
The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
Because, company incurred other costs in the course of its businesses, deducting from the gross profit and dividing the variance by the number of shares due yielded the recorded revenue of $(0.14). Investors should bear in mind that Medovex Corp. closed the last quarter with diluted shares due amounting to 16.27M.
Medovex Corp.’s debt exiting the last quarter amounted to 82,329%, indicating that the debt grew/declined by growing from the preceding period.
What is Medovex Corp.’s liquidity position and can it continue funding its businesses? The firm closed the previous quarter with cash balance of 1.99M%, having posted free cash flow of $(1.46M) during the last quarter. Net cash flow from businesses during the quarter was $(1.46M), resulting in net change in cash of $1.1M.
What about the performance of the firm?s balance sheet? Medovex Corp. had total assets of $2.4M at the end of the recent quarter, whereas total liabilities amounted to $506,244.
As for the Wall Street sentiment pertaining the stock, some analysts have remarked on Medovex Corp. so far, giving it an average recommendation of . Investors should understand that a call of 1 up to 1.24 implies the stock is a BUY, whereas recommendation of 2.75 up to 3.00 implies a stock is a SELL.